Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Severe Hypertriglyceridemia Clear all

Completed Phase 2 Interventional

Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

NCT01529424

View directory record Official record

Conditions: Hypertriglyceridemia
Interventions: ISIS apoC-III Rx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Farmville, North Carolina • Greenville, North Carolina • Kinston, North Carolina + 1 more

Source: ClinicalTrials.gov public record

Updated Jan 26, 2022 · Synced May 22, 2026, 12:51 AM EDT

Active, not recruiting Phase 3 Interventional

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

NCT06347016

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more

Source: ClinicalTrials.gov public record

Updated Oct 23, 2025 · Synced May 22, 2026, 12:51 AM EDT

Recruiting No phase listed Observational

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

NCT03087253

View directory record Official record

Conditions: Lipodystrophy (Genetic or Acquired, Non HIV)
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: Not listed

Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Source: ClinicalTrials.gov public record

Updated Mar 18, 2026 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 2 Interventional

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

NCT01594983

View directory record Official record

Conditions: Non Familial Chylocmicronemia Syndrome (Non-FCS)
Interventions: LCQ908, Fenofibrate, Fish Oil, Placebo of LCQ908, Placebo of fenofibrate, Placebo of fish oil; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Muscle Shoals, Alabama • Glendale, Arizona • Encinitas, California + 23 more

Source: ClinicalTrials.gov public record

Updated Dec 16, 2020 · Synced May 22, 2026, 12:51 AM EDT

Not listed Phase 3 Interventional

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: AKR-963; Drug
Lead sponsor: Trygg Pharma, Inc.; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Source: ClinicalTrials.gov public record

Updated Nov 23, 2011 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 3 Interventional

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

NCT05610280

View directory record Official record

Conditions: Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 1,478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more

Source: ClinicalTrials.gov public record

Updated Feb 9, 2026 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 3 Interventional

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

NCT03398005

View directory record Official record

Conditions: Hypertriglyceridemia
Interventions: CaPre, Placebo; Drug
Lead sponsor: Grace Therapeutics Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 69
States / cities: Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 57 more

Source: ClinicalTrials.gov public record

Updated Jan 17, 2020 · Synced May 22, 2026, 12:51 AM EDT

Active, not recruiting Phase 3 Interventional

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

NCT05852431

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: Pegozafermin, Placebo; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 22 Years and older

Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 73
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 65 more

Source: ClinicalTrials.gov public record

Updated Aug 6, 2025 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 2 Interventional Results available

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

NCT05355402

View directory record Official record

Conditions: Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more

Source: ClinicalTrials.gov public record

Updated Apr 22, 2026 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 2 Interventional Results available

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

NCT04720534

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: ARO-APOC3, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 33
States / cities: Beverly Hills, California • Palm Springs, California • Boca Raton, Florida + 26 more

Source: ClinicalTrials.gov public record

Updated Mar 23, 2026 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 3 Interventional

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

NCT05552326

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 63
States / cities: Birmingham, Alabama • Peoria, Arizona • Los Angeles, California + 51 more

Source: ClinicalTrials.gov public record

Updated Oct 21, 2025 · Synced May 22, 2026, 12:51 AM EDT

Active, not recruiting Phase 3 Interventional

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

NCT06347003

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Garden Grove, California • Lake Forest, California • Montclair, California + 42 more

Source: ClinicalTrials.gov public record

Updated Oct 26, 2025 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 2 Interventional Results available

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

NCT02944383

View directory record Official record

Conditions: Severe Hypertriglyceridemia, Mixed Dyslipidaemia
Interventions: Gemcabene, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Fort Payne, Alabama • Tucson, Arizona • Beverly Hills, California + 41 more

Source: ClinicalTrials.gov public record

Updated Jun 24, 2020 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 2 Interventional

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

NCT02250105

View directory record Official record

Conditions: Hypertriglyceridemia
Interventions: ARI-3037MO, Placebo; Drug
Lead sponsor: Arisaph Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older

Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Tustin, California • Louisville, Kentucky • Auburn, Maine + 2 more

Source: ClinicalTrials.gov public record

Updated Aug 7, 2016 · Synced May 22, 2026, 12:51 AM EDT

Terminated Phase 2 Interventional Results available

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

NCT04863014

View directory record Official record

Conditions: Hypertriglyceridemia
Interventions: evinacumab, Placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 32
States / cities: Newport Beach, California • New Haven, Connecticut • Boca Raton, Florida + 26 more

Source: ClinicalTrials.gov public record

Updated May 21, 2024 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT03011450

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: K-877, Fenofibrate, Placebo (for K-877); Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 129
States / cities: Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more

Source: ClinicalTrials.gov public record

Updated Oct 27, 2022 · Synced May 22, 2026, 12:51 AM EDT

Active, not recruiting Phase 3 Interventional

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 65
States / cities: Los Angeles, California • San Diego, California • Tarzana, California + 53 more

Source: ClinicalTrials.gov public record

Updated Nov 30, 2025 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older

Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Source: ClinicalTrials.gov public record

Updated Jul 14, 2015 · Synced May 22, 2026, 12:51 AM EDT

Recruiting Phase 3 Interventional

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT06880770

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Los Angeles, California • Santa Clarita, California • New Haven, Connecticut + 13 more

Source: ClinicalTrials.gov public record

Updated May 5, 2026 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 2 Interventional Results available

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

NCT04541186

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: Pegozafermin, Placebo; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 21 Years to 75 Years

Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 32
States / cities: La Mesa, California • San Francisco, California • Clearwater, Florida + 26 more

Source: ClinicalTrials.gov public record

Updated Jul 24, 2024 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 2 Interventional

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

NCT01968720

View directory record Official record

Conditions: Hyperlipidemias, Hypertriglyceridemia, Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases
Interventions: CAT-2003, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Indianapolis, Indiana • Auburn, Maine + 1 more

Source: ClinicalTrials.gov public record

Updated Aug 13, 2015 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 2 Interventional Results available

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

NCT03452228

View directory record Official record

Conditions: Severe Hypertriglyceridemia (sHTG)
Interventions: evinacumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Boca Raton, Florida • Atlanta, Georgia • Kansas City, Kansas + 6 more

Source: ClinicalTrials.gov public record

Updated Feb 15, 2023 · Synced May 22, 2026, 12:51 AM EDT

Recruiting Phase 2 Interventional

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

NCT07269210

View directory record Official record

Conditions: Severe Hypertriglyceridemia
Interventions: Solbinsiran, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 24 more

Source: ClinicalTrials.gov public record

Updated Apr 21, 2026 · Synced May 22, 2026, 12:51 AM EDT

Active, not recruiting Phase 3 Interventional

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

NCT06548100

View directory record Official record

Conditions: Generalized Lipodystrophy
Interventions: mibavademab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 2 Years and older

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Source: ClinicalTrials.gov public record

Updated Apr 6, 2026 · Synced May 22, 2026, 12:51 AM EDT